Log in | Register

Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective study

Joost Wauters| Ingrid Baar| Philippe Meersseman| Wouter Meersseman| Karolien Dams| Rudi De Paep| Katrien Lagrou| Alexander Wilmer| Philippe Jorens| Greet Hermans
Original
Volume 38, Issue 11 / November , 2012

Pages 1761 - 1768

Abstract

Purpose

Despite their controversial role, corticosteroids (CS) are frequently administered to patients with H1N1 virus infection with severe respiratory failure secondary to viral pneumonia. We hypothesized that invasive pulmonary aspergillosis (IPA) is a frequent complication in critically ill patients with H1N1 virus infection and that CS may contribute to this complication.

Methods

We retrospectively selected all adult patients with confirmed H1N1 virus infection admitted to the intensive care unit (ICU) of two tertiary care hospitals from September 2009 to March 2011. Differences in baseline factors, risk factors, and outcome parameters were studied between patients with and without IPA.

Results

Of 40 critically ill patients with confirmed H1N1, 9 (23 %) developed IPA 3 days after ICU admission. Five patients had proven and four had probable IPA. Significantly more IPA patients received CS within 7 days before ICU admission (78 versus 23 %, p = 0.002). IPA patients also received significantly higher doses of CS before ICU admission [hydrocortisone equivalent 800 (360–2,635) versus 0 (0–0) mg, p = 0.005]. On multivariate analysis, use of CS before ICU admission was independently associated with IPA [odds ratio (OR) 14.4 (2.0–101.6), p = 0.007].

Conclusions

IPA was diagnosed in 23 % of critically ill patients with H1N1 virus infection after a median of 3 days after ICU admission. Our data suggest that use of CS 7 days before ICU admission is an independent risk factor for fungal superinfection. These findings may have consequences for clinical practice as they point out the need for increased awareness of IPA, especially in those critically ill H1N1 patients already receiving CS.

Keywords

References

  1. Ramsey C, Kumar A (2011) H1N1: viral pneumonia as a cause of acute respiratory distress syndrome. Curr Opin Crit Care 17:64–71
    • View reference on PubMed
    • View reference on publisher's website
  2. Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009, Influenza Bautista E, Chotpitayasunondh T, Gao Z, Harper SA, Shaw M, Uyeki TM, Zaki SR, Hayden FG, Hui DS, Kettner JD, Kumar A, Lim M, Shindo N, Penn C, Nicholson KG (2010) Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 362:1708–1719
    • View reference on publisher's website
  3. Peter JV, John P, Graham PL, Moran JL, George IA, Bersten A (2008) Corticosteroids in the prevention and treatment of acute respiratory distress syndrome (ARDS) in adults: meta-analysis. BMJ 336:1006–1009
    • View reference on PubMed
    • View reference on publisher's website
  4. Tang BM, Craig JC, Eslick GD, Seppelt I, McLean AS (2009) Use of corticosteroids in acute lung injury and acute respiratory distress syndrome: a systematic review and meta-analysis. Crit Care Med 37:1594–1603
    • View reference on PubMed
    • View reference on publisher's website
  5. Domínguez-Cherit G, Lapinsky SE, Macias AE, Pinto R, Espinosa-Perez L, de la Torre A, Poblano-Morales M, Baltazar-Torres JA, Bautista E, Martinez A, Martinez MA, Rivero E, Valdez R, Ruiz-Palacios G, Hernández M, Stewart TE, Fowler RA (2009) Critically Ill patients with 2009 influenza A (H1N1) in Mexico. JAMA 302:1880–1887
    • View reference on PubMed
    • View reference on publisher's website
  6. Kumar A, Zarychanski R, Pinto R, Cook DJ, Marshall J, Lacroix J, Stelfox T, Bagshaw S, Choong K, Lamontagne F, Turgeon AF, Lapinsky S, Ahern SP, Smith O, Siddiqui F, Jouvet P, Khwaja K, McIntyre L, Menon K, Hutchison J, Hornstein D, Joffe A, Lauzier F, Singh J, Karachi T, Wiebe K, Olafson K, Ramsey C, Sharma S, Dodek P, Meade M, Hall R, Fowler RA, Canadian Critical Care Trials Group H1N1 Collaborative (2009) Critically ill patients with 2009 influenza A (H1N1) infection in Canada. JAMA 302:1872–1879
    • View reference on publisher's website
  7. ANZIC Influenza Investigators, Webb SA, Pettilä V, Seppelt I, Bellomo R, Bailey M, Cooper DJ, Cretikos M, Davies AR, Finfer S, Harrigan PW, Hart GK, Howe B, Iredell JR, McArthur C, Mitchell I, Morrison S, Nichol AD, Paterson DL, Peake S, Richards B, Stephens D, Turner A, Yung M (2009) Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med 361:1925–1934
    • View reference on PubMed
    • View reference on publisher's website
  8. Brun-Buisson C, Richard JC, Mercat A, Thiebaut AC, Brochard L (2011) Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. Am J Respir Crit Care Med 183:1200–1206
    • View reference on PubMed
    • View reference on publisher's website
  9. Kim SH, Hong SB, Yun SC, Choi WI, Ahn JJ, Lee YJ, Lee HB, Lim CM, Koh Y, Korean Society of Critical Care Medicine H1N1 Collaborative (2011) Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection: analytic strategy using propensity scores. Am J Respir Crit Care Med 183:1207–1214
    • View reference on PubMed
    • View reference on publisher's website
  10. Martin-Loeches I, Lisboa T, Rhodes A, Moreno RP, Silva E, Sprung C, Chiche JD, Barahona D, Villabon M, Balasini C, Pearse RM, Matos R, Rello J, ESICM H1N1 Registry Contributors (2011) Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1) v influenza A infection. Intensive Care Med 37:272–283
  11. Guinea J, Torres-Narbona M, Gijón P, Muñoz P, Pozo F, Peláez T, de Miguel J, Bouza E (2010) Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome. Clin Microbiol Infect 16:870–877
    • View reference on PubMed
  12. Meersseman W, Vandecasteele SJ, Wilmer A, Verbeken E, Peetermans WE, Van Wijngaerden E (2004) Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med 170:621–625
    • View reference on PubMed
    • View reference on publisher's website
  13. Lat A, Bhadelia N, Miko B, Furuya EY, Thompson GR 3rd (2010) Invasive aspergillosis after pandemic (H1N1) 2009. Emerg Infect Dis 16:971–973
    • View reference on PubMed
    • View reference on publisher's website
  14. Adalja AA, Sappington PL, Harris SP, Rimmele T, Kreit JW, Kellum JA, Boujoukos AJ (2011) Isolation of Aspergillus in three 2009 H1N1 influenza patients. Influenza Other Respir Viruses 5:225–229
    • View reference on publisher's website
  15. Garcia-Vidal C, Barba P, Arnan M, Moreno A, Ruiz-Camps I, Gudiol C, Ayats J, Ortí G, Carratalà J (2011) Invasive aspergillosis complicating pandemic influenza A (H1N1) infection in severely immunocompromised patients. Clin Infect Dis 53:e16–e19
    • View reference on PubMed
    • View reference on publisher's website
  16. Kim SH, Kim MN, Lee SO, Choi SH, Kim YS, Woo JH, Lim CM, Koh Y, Hong SB (2012) Fatal pandemic influenza A/H1N1 infection complicated by probable invasive pulmonary aspergillosis. Mycoses 55:189–192
    • View reference on PubMed
    • View reference on publisher's website
  17. Passouant O, Mateu P, Commandini M, Brenkle K, Just B (2011) Pulmonary aspergillosis in non-immunocompromised patient with acute respiratory distress syndrome during A (H1N1) infection. Ann Fr Anesth Reanim 30:e75–e76
    • View reference on PubMed
    • View reference on publisher's website
  18. Vehreschild JJ, Bröckelmann PJ, Bangard C, Verheyen J, Vehreschild MJ, Michels G, Wisplinghoff H, Cornely OA (2011) Pandemic 2009 influenza A (H1N1) virus infection coinciding with invasive pulmonary aspergillosis in neutropenic patients. Epidemiol Infect [Epub ahead]
  19. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Muñoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE; European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group, National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46:1813–1821
    • View reference on publisher's website
  20. Meersseman W, Lagrou K, Maertens J, Wilmer A, Hermans G, Vanderschueren S, Spriet I, Verbeken E, Van Wijngaerden E (2008) Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med 177:27–34
    • View reference on PubMed
    • View reference on publisher's website
  21. Stynen D, Goris A, Sarfati J, Latge JP (1995) A new sensitive sandwich enzyme-linked immunosorbent assay to detect galactofuran in patients with invasive aspergillosis. J Clin Microbiol 33:497–500
    • View reference on PubMed
  22. Sehulster L, Chinn RY (2003) Guidelines for environmental infection control in health-care facilities. Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 52:1–42
    • View reference on PubMed
  23. Vandewoude KH, Blot SI, Depuydt P, Benoit D, Temmerman W, Colardyn F, Vogelaers D (2006) Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients. Crit Care 10:R31
    • View reference on PubMed
    • View reference on publisher's website
  24. Bulpa PA, Dive AM, Garrino MG, Delos MA, Gonzalez MR, Evrard PA, Glupczynski Y, Installé EJ (2001) Chronic obstructive pulmonary disease patients with invasive pulmonary aspergillosis: benefits of intensive care? Intensive Care Med 27:59–67
  25. Garnacho-Montero J, Amaya-Villar R, Ortiz-Leyba C, León C, Alvarez-Lerma F, Nolla-Salas J, Iruretagoyena JR, Barcenilla F (2005) Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome. Crit Care 9:R191–R199
    • View reference on PubMed
    • View reference on publisher's website
  26. Meersseman W, Lagrou K, Maertens J, Van Wijngaerden E (2007) Invasive aspergillosis in the intensive care unit. Clin Infect Dis 45:205–216
    • View reference on PubMed
    • View reference on publisher's website
  27. Vandewoude KH, Blot SI, Benoit D, Colardyn F, Vogelaers D (2004) Invasive aspergillosis in critically ill patients: attributable mortality and excesses in length of ICU stay and ventilator dependence. J Hosp Infect 56:269–276
    • View reference on PubMed
    • View reference on publisher's website
  28. Clancy CJ, Nguyen MH (1998) Acute community-acquired pneumonia due to Aspergillus in presumably immunocompetent hosts: clues for recognition of a rare but fatal disease. Chest 114:629–634
    • View reference on PubMed
    • View reference on publisher's website
  29. Lewis DE, Gilbert BE, Knight V (1986) Influenza virus infection induces functional alterations in peripheral blood lymphocytes. J Immunol 137:3777–3781
    • View reference on PubMed
  30. Sedger LM, Hou S, Osvath SR, Glaccum MB, Peschon JJ, van Rooijen N, Hyland L (2002) Bone marrow B cell apoptosis during in vivo influenza virus infection requires TNF-alpha and lymphotoxin-alpha. J Immunol 169:6193–6201
    • View reference on PubMed
  31. Abbott JD, Fernando HV, Gurling K, Meade BW (1952) Pulmonary aspergillosis following post-influenzal bronchopneumonia treated with antibiotics. Br Med J 1:523–525
    • View reference on PubMed
    • View reference on publisher's website
  32. Mauad T, Hajjar LA, Callegari GD, da Silva LF, Schout D, Galas FR, Alves VA, Malheiros DM, Auler JO Jr, Ferreira AF, Borsato MR, Bezerra SM, Gutierrez PS, Caldini ET, Pasqualucci CA, Dolhnikoff M, Saldiva PH (2010) Lung pathology in fatal novel human influenza A (H1N1) infection. Am J Respir Crit Care Med 181:72–79
    • View reference on PubMed
    • View reference on publisher's website
  33. Lionakis MS, Kontoyiannis DP (2003) Glucocorticoids and invasive fungal infections. Lancet 362:1828–1838
    • View reference on PubMed
    • View reference on publisher's website
  34. Ng TT, Robson GD, Denning DW (1994) Hydrocortisone-enhanced growth of Aspergillus spp.: implications for pathogenesis. Microbiology 140(9):2475–2479
    • View reference on PubMed
    • View reference on publisher's website
  35. Giannella M, Alonso M, Garcia de Viedma D, Lopez Roa P, Catalán P, Padilla B, Muñoz P, Bouza E (2011) Prolonged viral shedding in pandemic influenza A (H1N1): clinical significance and viral load analysis in hospitalized patients. Clin Microbiol Infect 17:1160–1165
    • View reference on PubMed
    • View reference on publisher's website
  36. Xi X, Xu Y, Jiang L, Li A, Duan J, Du B (2010) Hospitalized adult patients with 2009 influenza A (H1N1) in Beijing, China: risk factors for hospital mortality. BMC Infect Dis 10:256
    • View reference on PubMed
  37. Li XW, Jiang RM, Guo JZ (2003) Glucocorticoid in the treatment of severe acute respiratory syndrome patients: a preliminary report. Zhonghua Nei Ke Za Zhi 42:378–381
    • View reference on PubMed

Sign In

Connect with ICM

Top 5 Articles Editors Picks Supplement